The prevalence of tyrosine kinase rearrangements in conventional papillary carcinoma is lower compared to that of other driver mutations, such as BRAF p.V600E and RAS. Rearrangements are uncommon in advanced tumors, but they have been reported in up to 5–25% of aggressive, high-grade non-anaplastic tumors and in up to 5–10% of anaplastic carcinomas (14, 19, 37, 52). The gene discussed is BRAF; the disease is thyroid gland papillary carcinoma.